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Objective: Adverse effects from medication vary with age. Weight gain with several psychotropics is well
known in adults but less information is available related to extent and complications of
psychotropic-induced weight gain in older psychiatric patients. We determined the relative incidence of 2
obesity-related conditions (diabetes and hypertension) in older psychiatric patients receiving antipsychotics,
antidepressants, and mood stabilizers.
Method: A population-based case–control study of all psychiatric patients aged 67 years or older in contact
with either specialist services or primary care using administrative data from Nova Scotia.
Results: We identified incident cases of diabetes (n = 608) and of hypertension (n = 1056), as well as an
equal number of control subjects for each condition. Amitryptiline, selective serotonin reuptake inhibitors
(SSRIs), and olanzapine were associated with an increased risk of presenting with hypertension 6 months
after initial prescription. By contrast, conventional antipsychotics were associated with a reduced incidence
of hypertension. Olanzapine was also significantly associated with diabetes after 6 months (ORadj = 2.58,
95% CI 1.12 to 5.92). The findings for SSRIs and olanzapine remained significant after adjusting for
potential confounders such as sociodemographic characteristics, schizophrenia, beta blockers, thiazide
diuretics, and corticosteroids.
Conclusions: Our results suggest that the association of psychotropics and 2 obesity-related conditions,
hypertension and diabetes, applies to older psychiatric patients as well as younger populations. Within drug
classes, there are drugs that have a greater association than others, and this may be a factor when choosing a
specific agent.
Can J Psychiatry. 2009;54(4):269–274.
Clinical Implications
 Psychotropics are widely used in older patients to treat various psychiatric disturbances, and this is reflected in
the disproportionately high use of these compounds in people aged 65 years or older. However, there are few
studies of possible obesity-related side effects in this population.
 The results of this study suggest that the association of psychotropics and possible obesity-related conditions
such as hypertension and diabetes applies to older psychiatric patients, as well as younger populations.
 Within drug classes, there are drugs that have a greater association than others, and this may be a factor when
choosing a specific agent.
Limitations
 We relied on routine administrative data that may be subject to recording and ascertainment bias. We may
therefore have underestimated the true incidence of diabetes and hypertension, and overestimated the association
between certain psychotropic and possible obesity-related conditions.
 We do not know whether our results for older psychiatric patients are generalizable to other populations until
further studies are undertaken in this area.
 As this was an epidemiologic study using administrative claims data, detailed clinical information or information
on risk factors such as smoking, physical activity, diet, or family history was not available. We were also unable
to evaluate the effect of treatment dose or compliance.
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The growing prevalence of obesity and obesity-related dis-orders, such as type II diabetes and hypertension, is a
major public health concern.1–4 Aside from poor diet and sed-
entary lifestyle, antipsychotic agents, mood stabilizers, and
several antidepressants can promote weight gain.5–8 With 1 in
5 Canadians having a psychiatric disorder during their life-
time and the use of psychotherapeutic drugs as second only to
cardiovascular drugs,9 psychotropic medications may con-
tribute to obesity and obesity-related disorders in Canada.
There is limited information on the longer-term effects of
psychotropic-induced weight gain. Numerous controlled tri-
als have reported short-term changes in glucose and choles-
terol levels, although long-term consequences are less clear.10
A large, noncommercial clinical trial in the United States indi-
cated that olanzapine was associated with higher rates of dis-
continuation for weight gain or metabolic effects.11
Results from observational analyses of administrative data-
bases are equivocal. A meta-analysis of 16 studies in patients
with psychoses from the United States reported that clozapine
and olanzapine showed an increased risk of diabetes, com-
pared with conventional or no antipsychotics, but risperidone
or quetiapine did not.10 However, other epidemiologic studies
found little difference between conventional and atypical
antipsychotics in increasing the risk of diabetes.12–14 One lim-
iting factor of many US studies is that they are restricted to
members of health care plans and therefore subject to selec-
tion bias.
There are still fewer data on people aged 65 years and older
even though they are more likely to receive psychotropics
than younger populations.15,16 They may also differ in terms of
obesity-related side-effects, as increasing age is independ-
ently associated with diabetes and hypertension.14 This
case–control study compares the proportion of older psychiat-
ric patients taking psychotropics who developed 2 obesity-
related conditions (diabetes and hypertension) with the pro-
portion taking psychotropics who developed neither condi-
tion. We also investigated whether there were any differences
between, and within, specific drug classes. We used the
administrative databases of the provincial health care and
pharmaceutical programs, which cover people aged 65 years
and older in Nova Scotia.17
Study Design and Analysis
We assessed the potential effect of the following
psychotropic drugs: high- and low-potency conventional
neuroleptics (based on chlorpromazine equivalents),18,19
olanzapine, quetiapine, risperidone, SSRIs, venlafaxine,
amitryptiline, lithium, and other mood stabilizers. We identi-
fied cases and controls using the following datasets:
 The Seniors’ Pharmacare database of claims by people
aged 65 years and older including duration of each
prescription
 The physician billings database of all fee-for-service
claims including date of service, ICD-9 and ICD-10
diagnoses, and patient demographics
 The Canadian Institute of Health Information DAD of
admissions, separation times, and diagnoses
 MHOIS of demographics, diagnoses, and care episodes
We defined cases as psychiatric patients who presented for
the first time with 1 of the 2 obesity-related conditions of
interest in either the DAD or physician billings databases for
the study period (January 1, 2001, to December 31, 2003).
We identified cases for each obesity-related condition sepa-
rately using the following ICD-9 codes (or ICD-10 equiva-
lents): diabetes (250) and hypertension (401). We checked
for the absence of these diagnoses in the DAD or physician
billings databases over the previous 5 years. We randomly
selected a control psychiatric patient for each case, matched
on age, sex, and previous health service use. The control
subjects had not presented with the obesity-related condition
of interest during the study period, or in the 5 years prior to
the matched case’s index diagnosis. Psychiatric patients were
identified using criteria from PHAC for the surveillance of
treated psychiatric disorder.20,21 The PHAC definition con-
sists of ICD-9 diagnoses from 290 to 319 inclusive, or
ICD-10 equivalents. Case and control subjects had to have
had at least one psychiatric record in DAD, physician billings
or MHOIS from April 1, 1989, to December 31, 2003, and be
eligible for the Senior Pharmacare Program on the study start
date (January 1, 2001). They also had to be aged 67 years and
older to allow a 2-year lead-in from initial eligibility, and
therefore sufficient time for exposure to a psychotropic pre-
scribed under the program.
We then compared the prescription rate for every
psychotropic under investigation for case and control
subjects. We included patients who had received 6 months or
more of that particular medication prior to presentation for
hypertension or diabetes. We used 6 months as studies of
ear ly-episode psychosis indicate that most
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Abbreviations used in this article
DAD Discharge Abstract Database
ICD International Classification of Diseases
MHOIS Mental Health Outpatient Data Information System
PHAC Public Health Agency of Canada
SSRI selective serotonin reuptake inhibitor
psychotropic-induced weight gain occurs within the first
6 months of starting medication.22,23 We also conducted sensi-
tivity analyses of changing this threshold to 3 months or more.
We assessed the effects of potential confounders for the out-
comes of interest including age (aged 80 years or older, mark-
ing the oldest 25% to 33% of the hypertensive or diabetic
sample), sex, socioeconomic class (divided into quarters),
schizophrenia, beta blockers, thiazide diuretics, and
corticosteroids.24,25 We used logistic regression to adjust for
any potential confounder that we found to be associated with
either outcome, as well as sex and age (the latter as a
continuous variable).
The Capital Health Research Ethics Board approved this
research.
Results
We identified 608 people with diabetes and 1056 people with
hypertension, plus an equal number of control subjects for
each condition.
Table 1 shows the results for diabetes. We found no statisti-
cally significant differences between the case and control
subjects in terms of potential confounders with the exception
of beta blockers, thiazide diuretics, and corticosteroids (Table
1). After adjusting for potential confounders, olanzapine was
significantly associated with diabetes following 6 months of
treatment (Table 1), and as soon as after 3 months of treatment
(ORadj = 2.38, 95% CI 1.12 to 5.07; P = 0.03).
Table 2 shows the results for hypertension. We found no sta-
tistically significant differences in the case and control
subjects in terms of potential confounders with the exception
of socioeconomic class, a diagnosis of schizophrenia, beta
blockers, and thiazide diuretics (Table 2). Amitriptyline,
SSRIs, and olanzapine were associated with an increased risk
of presenting with hypertension after 6 months of use. Con-
ventional neuroleptics were associated with a reduced risk of
presenting for hypertension (Table 2). For psychotropics,
SSRIs and olanzapine remained significantly associated with
hypertension after adjusting for potential confounders (Table
2). On sensitivity analysis, the results for olanzapine and
SSRIs were significant from 3 months onward (of use, respec-
tively, ORadj = 2.00, 95% CI 1.07 to 3.75; P = 0.03 and
ORadj = 1.34, 95% CI = 1.07 to 1.68; P = 0.01). Quetiapine was
associated with a reduced risk of hypertension at 3 months
(ORadj = 0.40, 95% CI 0.17 to 0.93; P = 0.03).
Discussion
Antipsychotics are widely used in older patients to treat vari-
ous psychiatric disturbances including delirium, dementia,
schizophrenia, delusional disorder, and psychotic mood dis-
orders. The frequency of their use is underlined by findings of
a disproportionately high use of antipsychotics and
benzodiazepines in geriatric patients, compared with those
aged 65 years and younger. In spite of their use, there are few
studies of side effects in this population. Available data on
side effects are generally confined to nursing home residents
and have not focused on obesity-related conditions.15
To our knowledge, this is the first population-based
case–control study of the problem in this age group. We eval-
uated the effect of a wide range of psychotropics on diabetes
and hypertension 6 months after prescription over a 3-year
period. The prescription of some psychotropics was associ-
ated with increases in the treated incidence of hypertension
and diabetes at a population level. Further, within drug
classes, some medications showed an increased association
with diabetes and hypertension in comparison with others
(for example, olanzapine, compared with other atypical
antipsychotics).
When comparing our data with other findings, one limitation
is that most studies have included both younger and older
ages, and have not been restricted to people aged 65 years and
older. Although, there is general agreement that certain
classes of psychotropics are associated with weight gain and
possible obesity-related disorder, there are conflicting data
for comparisons within classes. For instance, some studies
have found that olanzapine is associated with a greater risk of
developing diabetes , compared with other
antipsychotics,10,11,26,27 while others have not.12–14
This disparity in results in the general population may be due
to the presence of other drugs that may increase diabetes risk,
and differences in patient populations, analytical methods, or
the identification of diabetes and hypertension.11,14 We there-
fore do not know whether our results necessarily apply to
other populations.
There are several limitations to this study. We have no infor-
mation on risk factors such as physical activity or family his-
tory. We probably underestimated the true incidence of
hypertension and diabetes as we only counted recognized
cases, and up to one-third of diabetes in North America is
undiagnosed.10 The number of patients on some medications
was too small to allow analysis (for example, clozapine), or
might have been underpowered for accurate determination of
the risks of diabetes or hypertension during treatment with
those drugs. The concurrent prescription of other
psychotropics might have confounded the results of our anal-
yses of hypertension. However, this would not explain our
findings for diabetes where only one psychotropic was asso-
ciated with the outcome of interest. It is also possible that
increasing awareness of the association between particular
medications, such as olanzapine and the metabolic syn-
drome, might have led to ascertainment bias. However, this
would have applied more toward the end of the study period.
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Lastly, we did not evaluate the effect of treatment dose or
adherence in this analysis. However, we focused on psychiat-
ric patients where doses are higher than those for nonpsychi-
atric reasons. Further, the potential for psychotropic-induced
obesity for many drugs is not directly related to dose.
In conclusion, our results suggest that the association of
psychotropics and obesity-related conditions applies to older
patients as well as younger populations. Within drug classes,
some medications have a greater association than others, and
this may help clinicians choose an agent. These findings are
particularly relevant as people aged 65 years or older are more
likely than other age groups to be prescribed psychotropics.
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Table 1 Variables associated with diabetes
Variable
Cases
n = 608
Control subjects
n = 607 OR (95% CI) P
Adjusted
ORa (95% CI) P
Age, >80 years 196 195 1.00 (0.99–1.02) 0.90
Sex, male 193 193 1.00 (0.78–1.27) 0.98
Quarterly income
$49 562b 194 179
$40 184–$49 561 129 150 0.79 (0.58–1.08) 0.14
$33 776–$40 183 146 120 1.12 (0.82–1.54) 0.06
$0–$33 775 139 158 0.81 (0.60–1.10) 0.21
Schizophrenia 36 27 1.35 (0.81–2.26) 0.25
Beta blockers 167 132 1.77 (1.05–1.36) 0.02
Corticosteriods 52 30 2.86 (1.13–1.80) 0.01 1.78 (1.11–2.84) 0.02
Thiazide diuretics 140 82 2.58 (1.42–1.92) <0.001 1.90 (1.40–2.56) <0.001
Olanzapine 20 8 2.55 (1.11–5.82) 0.03 2.58 (1.12–5.92) 0.03
Risperidone 26 28 0.92 (0.54–1.60) 0.78
Quetiapine 9 11 0.72 (0.29–1.81) 0.49
Low-potency
conventional
antipsychoticsc
21 14 2.14 (0.96–4.78) 0.06
High-potency
conventional
antipsychoticsd
30 25 1.21 (0.70–2.08) 0.50
SSRIs 122 105 1.20 (0.90–1.60) 0.22
Venlafaxine 29 26 1.12 (0.65–1.92) 0.68
Amitriptyline 39 41 0.95 (0.60–1.49) 0.81
Lithium 15 18 0.83 (0.41–1.66) 0.59
Other mood stabilizers 33 35 0.94 (0.58–1.53) 0.80
a Adjusted for age (as a continuous variable), sex, beta blockers, thiazide diuretics, corticosteroids, and olanzapine
b Reference category
c Chlorpromazine, thioridazine, and methotrimeprazine
d Fluphenazine, haloperidol, droperidol, thiothixene, flupentixol, fluphenazine, trifluoperazine, perphenazine, pimozide, pipotiazine,
periciazine, and zuclopenthixol
population surveys. Although this research is based on data
obtained from the PHRU, the observations and opinions expressed
are those of the authors and do not represent those of PHRU.
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Résumé : Une étude épidémiologique des médicaments psychotropes et des maladies
chroniques liées à l’obésité chez les patients psychiatriques âgés
Objectif : Les effets indésirables de la médication varient avec l’âge. La prise de poids
qu’entraînent plusieurs psychotropes est bien connue chez les adultes, mais il y a moins
d’information relativement à la portée et aux complications de la prise de poids induite par les
psychotropes chez les patients psychiatriques âgés. Nous avons déterminé l’incidence relative de
2 affections liées à l’obésité (diabète et hypertension) chez des patients psychiatriques âgés recevant
des antipsychotiques, des antidépresseurs et des régulateurs de l’humeur.
Méthode : Une étude cas-témoin dans la population de tous les patients psychiatriques de 67 ans et
plus en contact avec des services spécialisés ou des soins primaires utilisant les données
administratives de la Nouvelle-Écosse.
Résultats : Nous avons identifié cas incidents de diabète (n = 608) et d’hypertension (n = 1056),
ainsi qu’un nombre égal de témoins pour chaque affection. L’amitryptiline, les inhibiteurs
spécifiques du recaptage de la sérotonine (ISRS), et l’olanzapine étaient associés à un risque accru
de présentation d’hypertension, 6 mois après la prescription initiale. Au contraire, les
antipsychotiques conventionnels étaient associés à une incidence réduite d’hypertension.
L’olanzapine était aussi significativement associée au diabète après 6 mois (ORadj = 2,58, 95 % IC
1,12 à 5,92). Les résultats des ISRS et de l’olanzapine demeuraient significatifs après ajustement
pour tenir compte des facteurs de confusion potentiels comme les caractéristiques
sociodémographiques, la schizophrénie, les bêtabloquants, les diurétiques thiazidiques, et les
corticostéroïdes.
Conclusions : Nos résultats suggèrent que l’association des psychotropes et des 2 affections liées à
l’obésité, le diabète et l’hypertension, s’applique aux patients psychiatriques âgés de même qu’aux
populations plus jeunes. Parmi les classes de médicaments, certains médicaments ont une
association plus marquée que d’autres, ce qui peut constituer un facteur lorsqu’on choisit un agent
spécifique.
